The aim of the current study was to prepare Amph-PVP-based nanoparticles covalently conjugated with DR5-specific antitumor cytokine, namely TRAIL mutant variant DR5-B, and to evaluate their in vitro cytotoxicity in 3D tumor spheroids. Here, TNFRSF10B is linked to neoplasm.